Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Plotkin, Scott R.
Merker, Vanessa L.
Halpin, Chris
Jennings, Dominique
McKenna, Michael J.
Harris, Gordon J.
and
Barker, Fred G.
2012.
Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2.
Otology & Neurotology,
Vol. 33,
Issue. 6,
p.
1046.
Liu, J.K.
2012.
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Yearbook of Neurology and Neurosurgery,
Vol. 2012,
Issue. ,
p.
180.
Minagar, A.
2012.
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Yearbook of Neurology and Neurosurgery,
Vol. 2012,
Issue. ,
p.
130.
Narita, Yoshitaka
2013.
Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors.
Japanese Journal of Clinical Oncology,
Vol. 43,
Issue. 6,
p.
587.
Crimmins, Michael
Banihashemi, Mohammed Amin
Gobin, Y. Pierre
Knopman, Jared
and
Patsalides, Athos
2014.
PanVascular Medicine.
p.
1.
Slusarz, Katherine M.
Merker, Vanessa L.
Muzikansky, Alona
Francis, Sanjeev A.
and
Plotkin, Scott R.
2014.
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.
Cancer Chemotherapy and Pharmacology,
Vol. 73,
Issue. 6,
p.
1197.
Versleijen, Michelle W.J.
Verbist, Berit M.
Mulder, Jef J.S.
de Geus-Oei, Lioe-Fee
and
van Herpen, Carla M.L.
2014.
Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2.
Clinical Nuclear Medicine,
Vol. 39,
Issue. 3,
p.
277.
London, Nyall R.
and
Gurgel, Richard K.
2014.
The role of vascular endothelial growth factor and vascular stability in diseases of the ear.
The Laryngoscope,
Vol. 124,
Issue. 8,
Sun, Shibin
and
Liu, Ali
2014.
Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Journal of Neurosurgery,
Vol. 121,
Issue. Suppl_2,
p.
143.
Crimmins, Michael
Banihashemi, Mohammad Amin
Gobin, Y. Pierre
Knopman, Jared
and
Patsalides, Athos
2015.
PanVascular Medicine.
p.
1.
Farschtschi, Said
Kollmann, Philipp
Dalchow, Carsten
Stein, Alexander
and
Mautner, Victor-Felix
2015.
Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
European Archives of Oto-Rhino-Laryngology,
Vol. 272,
Issue. 12,
p.
3857.
Crimmins, Michael
Banihashemi, Mohammed Amin
Gobin, Y. Pierre
Knopman, Jared
and
Patsalides, Athos
2015.
PanVascular Medicine.
p.
2613.
Sponghini, Andrea P.
Platini, Francesca
Rondonotti, David
and
Soffietti, Riccardo
2015.
Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage.
Tumori Journal,
Vol. 101,
Issue. 6,
p.
e167.
McCabe, Martin G
and
Evans, Dafydd Gareth
2015.
Pathogenesis and management of type 2 neurofibromatosis.
Expert Opinion on Orphan Drugs,
Vol. 3,
Issue. 3,
p.
281.
Alanin, Mikkel Christian
Klausen, Camilla
Caye-Thomasen, Per
Thomsen, Carsten
Fugleholm, Kaare
Poulsgaard, Lars
Lassen, Ulrik
Mau-Sorensen, Morten
and
Hofland, Kenneth Francis
2015.
The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
European Archives of Oto-Rhino-Laryngology,
Vol. 272,
Issue. 12,
p.
3627.
Ruggieri, Martino
Praticò, Andrea Domenico
and
Evans, Dafydd Gareth
2015.
Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Seminars in Pediatric Neurology,
Vol. 22,
Issue. 4,
p.
240.
Li, Ka-Loh
Djoukhadar, Ibrahim
Zhu, Xiaoping
Zhao, Sha
Lloyd, Simon
McCabe, Martin
McBain, Catherine
Evans, D. Gareth
and
Jackson, Alan
2016.
Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Neuro-Oncology,
Vol. 18,
Issue. 2,
p.
275.
Han, Jung Ho
Kim, Dong Gyu
Chung, Hyun-Tai
Paek, Sun Ha
and
Jung, Hee-Won
2016.
Advances and Technical Standards in Neurosurgery.
Vol. 43,
Issue. ,
p.
3.
LIU, PENGFEI
YAO, QINGYU
LI, NA
LIU, YONGLIANG
WANG, YUGUO
LI, MENG
LI, ZEFU
LI, JIANMIN
and
LI, GANG
2016.
Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.
Oncology Letters,
Vol. 11,
Issue. 5,
p.
2981.
Goutagny, S.
and
Kalamarides, M.
2018.
Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Neurochirurgie,
Vol. 64,
Issue. 5,
p.
370.